8-羟基-1,6-二氮杂萘-7-羧酸 | 410542-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 8-羟基-1,6-二氮杂萘-7-羧酸
• 英文名称: 8-hydroxy-1,6-naphthyridine-7-carboxylic Acid
• 英文别名: 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid
• CAS: 410542-70-0
• 化学式: C₉H₆N₂O₃
• 分子量: 190.158
• InChiKey: YKJPPGSOGMPOFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.3
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  8-羟基-1,6-二氮杂萘-7-羧酸 、 苯乙酸肼 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氯氧磷 、 sodium methylate 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 18.75h， 生成 7-(5-benzyl-[1,3,4]oxadiazol-2-yl)-[1,6]naphthyridin-8-ol
  参考文献：
  名称：

  [EN] NAPHTHYRIDINE INTEGRASE INHIBITORS
  [FR] INIHBITEURS DE L'INTEGRASE DE LA NAPHTYRIDINE

  摘要：

  公开号：

  WO2004101512A3
• 作为产物：
  描述：

  8-羟基-1,6-萘啶-7-羧酸乙酯 在 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以87%的产率得到8-羟基-1,6-二氮杂萘-7-羧酸
  参考文献：
  名称：

  The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore

  摘要：

  A series of HIV-1 integrase inhibitors containing a novel metal binding motif consisting of the 8-hydroxy1,6-naphthyridine core and either an oxadiazole or triazole has been identified. The design of the key structural components was based on a two-metal coordination pharmacophore. This report presents initial structure-activity data that shows the new chelation architecture delivers potent inhibition in both enzymatic and antiviral assays. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.090

文献信息

• Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
  申请人：——

  公开号：US20030055071A1

  公开（公告）日：2003-03-20

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  描述了包括某些喹啉羧酰胺和萘啉羧酰胺衍生物在内的氮杂萘基羧酰胺衍生物。这些化合物是HIV整合酶的抑制剂和HIV复制的抑制剂，可用于预防或治疗HIV感染和治疗艾滋病，作为化合物或药学上可接受的盐，或作为药物组合物中的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了预防、治疗或延缓艾滋病发作的方法，以及预防或治疗HIV感染的方法。
• Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
  申请人：——

  公开号：US20040034221A1

  公开（公告）日：2004-02-19

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  本文描述了包括某些喹啉羧酰胺和萘啶羧酰胺衍生物在内的Aza-和polyaza-萘啶基羧酰胺衍生物，作为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物作为化合物或药物可接受的盐，或作为制药组合物中的成分，可用于预防或治疗HIV感染和治疗艾滋病，可选地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。本文还描述了预防、治疗或延迟艾滋病发作的方法以及预防或治疗HIV感染的方法。
• Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
  申请人：——

  公开号：US20040044207A1

  公开（公告）日：2004-03-04

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating, or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  本文描述了包括某些喹啉羧酰胺和萘啶羧酰胺衍生物在内的Aza-和polyaza-萘基羧酰胺衍生物，作为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物可作为化合物或药物可接受的盐，或作为药物组成部分，可选与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用，用于预防或治疗HIV感染和治疗艾滋病。还描述了预防、治疗或延迟艾滋病发作的方法以及预防或治疗HIV感染的方法。
• Phosphonate analogs of HIV integrase inhibitor compounds
  申请人：Cai R. Zhenhong

  公开号：US20060116356A1

  公开（公告）日：2006-06-01

  Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  本发明揭示了至少具有一个膦酸酯基团的新型HIV整合酶抑制剂化合物，其保护中间体以及用于抑制HIV整合酶的方法。
• Pre-organized tricyclic integrase inhibitor compounds
  申请人：GILEAD SCIENCES, INC.

  公开号：US20040157804A1

  公开（公告）日：2004-08-12

  Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. 1 A 1 and A 2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl. Q is N, + NR, or CR 4 . The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.

  本发明揭示了以下结构的三环化合物、其保护中间体以及抑制HIV整合酶的方法。其中，1A1和A2是形成五、六或七元环的基团。L是连接Ar环原子和N原子的键或连接器。X为O、S或取代氮。Ar为芳基或杂环芳基。Q为N、+NR或CR4。芳基碳可以独立地被取代为除氢以外的取代基。化合物可以包括共价连接在任何位点的前药基团。